Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus

Research output: Contribution to journalArticle

259 Citations (Scopus)

Abstract

Recently, nicotinic acid has been recommended as a first-line hypolipidemic drug. To determine the effectiveness of nicotinic acid in dyslipidemic patients with non-insulin-dependent diabetes mellitus, 13 patients were treated in a randomized crossover trial. Patients received either nicotinic acid (1.5 g three times daily) or no therapy (control period) for 8 weeks each. Compared with the control period, nicotinic acid therapy reduced the plasma total cholesterol level by 24%, plasma triglyceride level by 45%, very-low-density lipoprotein cholesterol level by 58%, and low-density lipoprotein cholesterol level by 15%, and it increased the high-density lipoprotein cholesterol level by 34%. However, nicotinic acid therapy resulted in the deterioration of glycemic control, as evidenced by a 16% increase in mean plasma glucose concentrations, a 21% increase in glycosylated hemoglobin levels, and the induction of marked glycosuria in some patients. Furthermore, a consistent increase in plasma uric acid levels was observed. Therefore, despite improvement in lipid and lipoprotein concentrations, because of worsening hyperglycemia and the development of hyperuricemia, nicotinic acid must be used with caution in patients with non-insulin-dependent diabetes mellitus with dyslipidemia. We suggest that the drug not be used as a first-line hypolipidemic drug in patients with non-insulin-dependent diabetes mellitus.

Original languageEnglish (US)
Pages (from-to)723-726
Number of pages4
JournalJournal of the American Medical Association
Volume264
Issue number6
StatePublished - Aug 8 1990

Fingerprint

Niacin
Dyslipidemias
Type 2 Diabetes Mellitus
Hypolipidemic Agents
Therapeutics
Glycosuria
VLDL Cholesterol
Hyperuricemia
Glycosylated Hemoglobin A
Uric Acid
Hyperglycemia
LDL Cholesterol
Cross-Over Studies
HDL Cholesterol
Lipoproteins
Triglycerides
Cholesterol
Lipids
Glucose
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{966532d5ad904a708c91f1373e6c0f21,
title = "Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus",
abstract = "Recently, nicotinic acid has been recommended as a first-line hypolipidemic drug. To determine the effectiveness of nicotinic acid in dyslipidemic patients with non-insulin-dependent diabetes mellitus, 13 patients were treated in a randomized crossover trial. Patients received either nicotinic acid (1.5 g three times daily) or no therapy (control period) for 8 weeks each. Compared with the control period, nicotinic acid therapy reduced the plasma total cholesterol level by 24{\%}, plasma triglyceride level by 45{\%}, very-low-density lipoprotein cholesterol level by 58{\%}, and low-density lipoprotein cholesterol level by 15{\%}, and it increased the high-density lipoprotein cholesterol level by 34{\%}. However, nicotinic acid therapy resulted in the deterioration of glycemic control, as evidenced by a 16{\%} increase in mean plasma glucose concentrations, a 21{\%} increase in glycosylated hemoglobin levels, and the induction of marked glycosuria in some patients. Furthermore, a consistent increase in plasma uric acid levels was observed. Therefore, despite improvement in lipid and lipoprotein concentrations, because of worsening hyperglycemia and the development of hyperuricemia, nicotinic acid must be used with caution in patients with non-insulin-dependent diabetes mellitus with dyslipidemia. We suggest that the drug not be used as a first-line hypolipidemic drug in patients with non-insulin-dependent diabetes mellitus.",
author = "Abhimanyu Garg and Grundy, {Scott M}",
year = "1990",
month = "8",
day = "8",
language = "English (US)",
volume = "264",
pages = "723--726",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus

AU - Garg, Abhimanyu

AU - Grundy, Scott M

PY - 1990/8/8

Y1 - 1990/8/8

N2 - Recently, nicotinic acid has been recommended as a first-line hypolipidemic drug. To determine the effectiveness of nicotinic acid in dyslipidemic patients with non-insulin-dependent diabetes mellitus, 13 patients were treated in a randomized crossover trial. Patients received either nicotinic acid (1.5 g three times daily) or no therapy (control period) for 8 weeks each. Compared with the control period, nicotinic acid therapy reduced the plasma total cholesterol level by 24%, plasma triglyceride level by 45%, very-low-density lipoprotein cholesterol level by 58%, and low-density lipoprotein cholesterol level by 15%, and it increased the high-density lipoprotein cholesterol level by 34%. However, nicotinic acid therapy resulted in the deterioration of glycemic control, as evidenced by a 16% increase in mean plasma glucose concentrations, a 21% increase in glycosylated hemoglobin levels, and the induction of marked glycosuria in some patients. Furthermore, a consistent increase in plasma uric acid levels was observed. Therefore, despite improvement in lipid and lipoprotein concentrations, because of worsening hyperglycemia and the development of hyperuricemia, nicotinic acid must be used with caution in patients with non-insulin-dependent diabetes mellitus with dyslipidemia. We suggest that the drug not be used as a first-line hypolipidemic drug in patients with non-insulin-dependent diabetes mellitus.

AB - Recently, nicotinic acid has been recommended as a first-line hypolipidemic drug. To determine the effectiveness of nicotinic acid in dyslipidemic patients with non-insulin-dependent diabetes mellitus, 13 patients were treated in a randomized crossover trial. Patients received either nicotinic acid (1.5 g three times daily) or no therapy (control period) for 8 weeks each. Compared with the control period, nicotinic acid therapy reduced the plasma total cholesterol level by 24%, plasma triglyceride level by 45%, very-low-density lipoprotein cholesterol level by 58%, and low-density lipoprotein cholesterol level by 15%, and it increased the high-density lipoprotein cholesterol level by 34%. However, nicotinic acid therapy resulted in the deterioration of glycemic control, as evidenced by a 16% increase in mean plasma glucose concentrations, a 21% increase in glycosylated hemoglobin levels, and the induction of marked glycosuria in some patients. Furthermore, a consistent increase in plasma uric acid levels was observed. Therefore, despite improvement in lipid and lipoprotein concentrations, because of worsening hyperglycemia and the development of hyperuricemia, nicotinic acid must be used with caution in patients with non-insulin-dependent diabetes mellitus with dyslipidemia. We suggest that the drug not be used as a first-line hypolipidemic drug in patients with non-insulin-dependent diabetes mellitus.

UR - http://www.scopus.com/inward/record.url?scp=0025148561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025148561&partnerID=8YFLogxK

M3 - Article

VL - 264

SP - 723

EP - 726

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 6

ER -